Prosthetic Joint InfectionDiafilmNCT03784807
New Strategies for Biofilm Related Infections
An observational study of Prosthetic Joint Infection, run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio at 1 site in Italy.
Trial summary
This study aims to develop new assays for synovial fluid analysis able to improve diagnosis of prosthetic joint infections. In particular, use of synovial calprotectin as marker of infection, confocal laser scanning microscopy (CLSM) analysis and methods to assess antimicrobial susceptibility will be evaluated in… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Prosthetic Joint Infection
- What is being tested?
- synovial calprotectin, confocal laser microscopy
- How many people
- 99 participants
- Where
- 1 siteItaly
- Study dates
- 2 Nov 2018to 30 Nov 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with osteoarticular or prosthetic joint infection
Who may be able to join
- Diagnosis of implant failure or osteoarticular infections
- Collection of a sufficient amount of synovial fluid
- Informed Consent signed
Who cannot join
- Patients not fulfilling the inclusion criteria
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
IRCCS Istituto Ortopedico Galeazzi
Milan, MI, 20161
Elena Cittera, MSc, 00390266214057, elena.cittera@grupposandonato.it
Elena De Vecchi, MSc
About this study
Official title: New Strategies for Diagnosis and Management of Biofilm Related Infections
This study aims to develop new assays for synovial fluid analysis able to improve diagnosis of prosthetic joint infections. In particular, use of synovial calprotectin as marker of infection, confocal laser scanning microscopy (CLSM) analysis and methods to assess antimicrobial susceptibility will be evaluated in synovial fluids collected from patients with septic and aseptic failure of the prosthetic implant.
Read the detailed description
Infection of prosthetic joints is a common complication that may occur any time after implantation. These infections require a prompt and accurate diagnosis to ensure an optimal surgical and medical management of infected patient. Despite acute infections occurring in the first weeks after surgery are easy to diagnose or when they are associated to bacteremia, diagnosis becomes challenging when infection develops for several months before diagnosis or it is caused by low virulent pathogens. Prosthetic joint infections and more widely osteo-articular infections represent the classic biofilm related infections. Biofilm is usually defined as a microbial community enveloped in a self-produced polymeric matrix. Biofilm production allows bacteria to strictly adhere to inert and biotic substrates, evade host defenses and resist to antibiotics by building a physical barrier to penetration of antimicrobials and favoring dissemination of determinants of resistance. Microbiological cultures contribute to diagnosis of infection, providing identification of the pathogen and, most importantly, definition of antibiotic susceptibility. Nonetheless, in about 15-20% of cases, culture fails to growth the pathogen. Diagnosis of prosthetic joint infection may occur either pre- or intra-operatively. In both cases analysis of synovial fluid is crucial, especially when performed before surgery when results from culture, leukocyte esterase, alpha defensin test, leukocyte count and differential may lead to define the most accurate strategy to approach patients with implant failure. However, culture of synovial fluid is characterized by a limited sensitivity in respect, for instance to culture of periprosthetic tissues or implant components. One of the causes of the lower sensitivity of synovial fluid culture might be the presence of the so called "biofilm like aggregates", agglomerates of microorganisms embedded in a matrix which has been hypothesized to act as a protective barrier. Leukocyte esterase test may give false positive results in samples strongly contaminated by blood or with metal on metal reaction, while the high costs for alpha defensin determination markedly limited its use. On the other hand, studies aiming to evaluate other synovial markers of infections like calprotectin are insufficient to support their use in routine diagnosis of prosthetic joint infection.
An alternative approach to diagnosis of these infections could be represented by use of confocal laser scanning microscopy (CLSM) which allows to detect microorganisms in synovial fluid and in tissues. This novel approach could also be used for a "real time" diagnosis during surgery while waiting for culture results.
Another issue in diagnosis of prosthetic joint infections is related to assessment of antimicrobial susceptibility. In fact, it is well known that biofilm embedded bacteria are more resistant to antibiotics than their planktonic counterpart. Since available methods for determination of antibiotic susceptibility are based on planktonic cells, it may be hypothesized that they underestimate the real antimicrobial concentration able to inhibit growth of bacteria embedded in a biofilm as occur during infection. Although several methods have been proposed to evaluate antimicrobial susceptibility pattern of biofilm microorganisms, none of them has been proposed for routinely use. However, in some cases when therapy fails to eradicate infection, evaluation of antibiotic susceptibility of biofilm embedded bacteria could provide important information to optimize antimicrobial therapy.
Therefore, diagnosis of biofilm related infections, particularly prosthetic ones is quite far from being optimized. In this sense, development of a panel able to shorten turn around time of microbiological analyses and to improve patient management could significantly ameliorate approach to patients, limiting worsening in patient's quality of life and reducing costs for health system.
- Conditions
- Prosthetic Joint Infection
- Being tested
- synovial calprotectin, confocal laser microscopy
- Keywords
- synovial fluid analysis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
synovial calprotectin, confocal laser microscopyDiagnostic test
Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
| Study group | Role | What they receive |
|---|---|---|
| Infected | Patients with prosthetic joint or osteoarticular infection Receives: Diagnostic Test: synovial calprotectin, confocal laser microscopy | |
| Not infected | Patients with implant failure not due to infection Receives: Diagnostic Test: synovial calprotectin, confocal laser microscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of analytical performance of calprotectin and CLSM for diagnosis of prosthetic joint infections
Sensitivity, specificity, predictive values and diagnostic accuracy of calprotectin and CLSM will be calculated and compared to those of assays already used for diagnosis of prosthetic joint infections
Measured: preoperative visit or during surgery
Secondary outcomes (1)
Improvement in antibiotic therapy applying data obtained from antibiotic susceptibility testing on biofilm
Antimicrobial profiles obtained on biofilm bacteria will be compared with those obtained with traditional methods on planktonic cells
Measured: Afetr isolation of the pathogen, within 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2018
- Study start2 Nov 2018
- Primary completion30 Sep 2020 (estimated)
- Study completion30 Nov 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prosthetic Joint InfectionStudies of the same condition, open and under way.
- More trials run by I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 99 participants (estimated)
Sponsor and investigators
- Lead sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Elena De Vecchi, MSc, Principal investigator, IRCCS Istituto Ortopedico Galeazzi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03784807
- Sponsor's protocol ID
- Diafilm
- Acronym
- Diafilm
- Status last verified
- Dec 2018
- First submitted
- 6 Dec 2018
- Last updated
- 24 Dec 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Primary and secondary outcomes measures for all participants to the study will be made available
Study at a glance
From the registry record, last updated by the sponsor on 24 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- New Strategies for Diagnosis and Management of Biofilm Related Infections
- ClinicalTrials.gov ID
- NCT03784807
- Acronym / sponsor ID
- Diafilm / Diafilm
- Conditions
- Prosthetic Joint Infection
- Keywords
- synovial fluid analysis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 99 participants (estimated)
- Lead sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioUniversity, hospital or other
- Study start
- 2 Nov 2018 (actual)
- Primary completion
- 30 Sep 2020 (estimated)
- Study completion
- 30 Nov 2020 (estimated)
- First posted
- 24 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to develop new assays for synovial fluid analysis able to improve diagnosis of prosthetic joint infections. In particular, use of synovial calprotectin as marker of infection, confocal laser scanning microscopy (CLSM) analysis and methods to assess antimicrobial susceptibility will be evaluated in synovial fluids collected from patients with septic and aseptic failure of the prosthetic implant.
Detailed description
Infection of prosthetic joints is a common complication that may occur any time after implantation. These infections require a prompt and accurate diagnosis to ensure an optimal surgical and medical management of infected patient. Despite acute infections occurring in the first weeks after surgery are easy to diagnose or when they are associated to bacteremia, diagnosis becomes challenging when infection develops for several months before diagnosis or it is caused by low virulent pathogens. Prosthetic joint infections and more widely osteo-articular infections represent the classic biofilm related infections. Biofilm is usually defined as a microbial community enveloped in a self-produced polymeric matrix. Biofilm production allows bacteria to strictly adhere to inert and biotic substrates, evade host defenses and resist to antibiotics by building a physical barrier to penetration of antimicrobials and favoring dissemination of determinants of resistance. Microbiological cultures contribute to diagnosis of infection, providing identification of the pathogen and, most importantly, definition of antibiotic susceptibility. Nonetheless, in about 15-20% of cases, culture fails to growth the pathogen. Diagnosis of prosthetic joint infection may occur either pre- or intra-operatively. In both cases analysis of synovial fluid is crucial, especially when performed before surgery when results from culture, leukocyte esterase, alpha defensin test, leukocyte count and differential may lead to define the most accurate strategy to approach patients with implant failure. However, culture of synovial fluid is characterized by a limited sensitivity in respect, for instance to culture of periprosthetic tissues or implant components. One of the causes of the lower sensitivity of synovial fluid culture might be the presence of the so called "biofilm like aggregates", agglomerates of microorganisms embedded in a matrix which has been hypothesized to act as a protective barrier. Leukocyte esterase test may give false positive results in samples strongly contaminated by blood or with metal on metal reaction, while the high costs for alpha defensin determination markedly limited its use. On the other hand, studies aiming to evaluate other synovial markers of infections like calprotectin are insufficient to support their use in routine diagnosis of prosthetic joint infection.
An alternative approach to diagnosis of these infections could be represented by use of confocal laser scanning microscopy (CLSM) which allows to detect microorganisms in synovial fluid and in tissues. This novel approach could also be used for a "real time" diagnosis during surgery while waiting for culture results.
Another issue in diagnosis of prosthetic joint infections is related to assessment of antimicrobial susceptibility. In fact, it is well known that biofilm embedded bacteria are more resistant to antibiotics than their planktonic counterpart. Since available methods for determination of antibiotic susceptibility are based on planktonic cells, it may be hypothesized that they underestimate the real antimicrobial concentration able to inhibit growth of bacteria embedded in a biofilm as occur during infection. Although several methods have been proposed to evaluate antimicrobial susceptibility pattern of biofilm microorganisms, none of them has been proposed for routinely use. However, in some cases when therapy fails to eradicate infection, evaluation of antibiotic susceptibility of biofilm embedded bacteria could provide important information to optimize antimicrobial therapy.
Therefore, diagnosis of biofilm related infections, particularly prosthetic ones is quite far from being optimized. In this sense, development of a panel able to shorten turn around time of microbiological analyses and to improve patient management could significantly ameliorate approach to patients, limiting worsening in patient's quality of life and reducing costs for health system.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Infected | – | Diagnostic Test: synovial calprotectin, confocal laser microscopyPatients with prosthetic joint or osteoarticular infection |
| Not infected | – | Diagnostic Test: synovial calprotectin, confocal laser microscopyPatients with implant failure not due to infection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with osteoarticular or prosthetic joint infection
Key inclusion criteria (3 listed)
- Diagnosis of implant failure or osteoarticular infections
- Collection of a sufficient amount of synovial fluid
- Informed Consent signed
Key exclusion criteria (1 listed)
- Patients not fulfilling the inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| synovial calprotectin, confocal laser microscopyCalprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria | Diagnostic test | Infected, Not infected |
Primary outcome
Assessment of analytical performance of calprotectin and CLSM for diagnosis of prosthetic joint infections
Time frame: preoperative visit or during surgery
Sensitivity, specificity, predictive values and diagnostic accuracy of calprotectin and CLSM will be calculated and compared to those of assays already used for diagnosis of prosthetic joint infections
1 secondary outcome
Improvement in antibiotic therapy applying data obtained from antibiotic susceptibility testing on biofilm
Time frame: Afetr isolation of the pathogen, within 2 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Dec 2018.
- Individual participant dataSharing planned: Yes. Primary and secondary outcomes measures for all participants to the study will be made available
Related trials for Prosthetic Joint Infection
Recruiting
Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection
Prosthetic Joint Infection of Knee
RecruitingPhase 2
A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants
Prosthetic Joint Infection (PJI)
RecruitingPhase 2/3
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Prosthetic-joint Infection
Not yet recruitingObservational study
oneKNEE - Prospective, Non-interventional, Multicenter PMCF-Study
Arthroplasty, Arthroplasty Replacement, Knee
Active, not recruiting
CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee
Revision Total Hip Arthroplasty (RTHA), Revision Total Knee Arthroplasty
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elena De Vecchi, MSc principal investigator
IRCCS Istituto Ortopedico Galeazzi
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prosthetic Joint Infection, run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Elena Cittera, MSc (00390266214057, elena.cittera@grupposandonato.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of analytical performance of calprotectin and CLSM for diagnosis of prosthetic joint infections (time frame: preoperative visit or during surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2018.